DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21992/S-020

SUPPLEMENT APPROVAL

Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer
Attention: Lauren (Washam) Ingram
Manager
Worldwide Regulatory Strategy, Pfizer
PO Box 8299
Philadelphia, PA 19101-8299

Dear Mrs. Ingram:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 7, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Pristiq (desvenlafaxine) Extended-Release Tablets.

This "Changes Being Effected" supplemental new drug application provides for the inclusion of vertigo as an adverse drug reaction in **Table 3: Common Adverse Reactions: Percentages of Patients (> 2% in any Fixed-Dose Group) in MDD 8-Week Placebo-Controlled Studies** found in Section 6.1 Clinical Studies Experience.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements and any annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including "Changes Being Effects" (CBE) supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sharonjit Sagoo, Regulatory Project Manager, at (301) 796-0431.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
01/31/2011